- Home
- OKYO vs PRLD Comparison
OKYO vs PRLD Comparison
Compare OKYO & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- PRLD
- Stock Information
- Founded
- OKYO 2007
- PRLD 2016
- Country
- OKYO United Kingdom
- PRLD United States
- Employees
- OKYO N/A
- PRLD N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- OKYO Health Care
- PRLD Health Care
- Exchange
- OKYO Nasdaq
- PRLD Nasdaq
- Market Cap
- OKYO 85.0M
- PRLD 69.1M
- IPO Year
- OKYO 2022
- PRLD 2020
- Fundamental
- Price
- OKYO $2.24
- PRLD $1.42
- Analyst Decision
- OKYO Strong Buy
- PRLD Strong Buy
- Analyst Count
- OKYO 1
- PRLD 3
- Target Price
- OKYO $7.00
- PRLD $4.00
- AVG Volume (30 Days)
- OKYO 112.8K
- PRLD 290.5K
- Earning Date
- OKYO 07-18-2025
- PRLD 11-05-2025
- Dividend Yield
- OKYO N/A
- PRLD N/A
- EPS Growth
- OKYO N/A
- PRLD N/A
- EPS
- OKYO N/A
- PRLD N/A
- Revenue
- OKYO N/A
- PRLD $7,000,000.00
- Revenue This Year
- OKYO N/A
- PRLD N/A
- Revenue Next Year
- OKYO N/A
- PRLD N/A
- P/E Ratio
- OKYO N/A
- PRLD N/A
- Revenue Growth
- OKYO N/A
- PRLD N/A
- 52 Week Low
- OKYO $0.90
- PRLD $0.61
- 52 Week High
- OKYO $3.35
- PRLD $2.08
- Technical
- Relative Strength Index (RSI)
- OKYO 47.57
- PRLD 60.29
- Support Level
- OKYO $1.93
- PRLD $1.33
- Resistance Level
- OKYO $2.19
- PRLD $1.63
- Average True Range (ATR)
- OKYO 0.18
- PRLD 0.18
- MACD
- OKYO 0.02
- PRLD 0.01
- Stochastic Oscillator
- OKYO 45.65
- PRLD 49.42
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.